Stakeholders now confront the challenge of navigating the HTA review options paper, with its range of complex proposals, but also preparing for the implementation of those accepted by the Albanese Government.
The industry will need to construct a new capability to manage this change
February 2, 2024 Latest NewsBioPharmaComment
Latest Video
New Stories
-
From constitutional promise to creaking system - the PBS at 80
September 16, 2026 - - Latest News -
Young Australians badly misjudge when fertility starts to decline, new survey finds
September 16, 2026 - - Latest News -
A shorter name and bolder blue for Novo in global rebrand
September 15, 2026 - - Latest News -
New research points to a 'Doctor gap' holding back clinical trial participation in Australia
September 15, 2026 - - Latest News -
Persistent fatigue could be an overlooked sign of liver disease
September 15, 2026 - - Latest News -
Australia's 2026 flu vaccination season barely moves the needle on uptake
September 15, 2026 - - Latest News -
Noxopharm moves lupus skin therapy toward next human trial
September 14, 2026 - - Australian Biotech
